ClinicalTrialsFinder
RecruitingPhase 2NCT05468073

Therapeutic Evaluation of Low-dose IL-2-based Immunomodulatory Approach in Patients With Early AD

Sponsor

Centre Hospitalier St Anne

Enrollment

45 participants

Start Date

Oct 11, 2022

Study Type

INTERVENTIONAL

Conditions

Alzheimer Disease

Summary

Study aims at evaluating the therapeutic efficacy and safety of low-dose IL-2 immunomodulatory treatment in patients with early AD, in a phase II, randomized, double blind, placebo-controlled phase II clinical trial. Patients with AD at early stage will be recruited and randomized (2:1) in each treatment group. The primary endpoint is the rate of decline assessed through CDR change at 18 months between the placebo group and the treated patients.

Eligibility

Min Age: 18 Years

Inclusion Criteria12

  • Patients aged \> 18
  • Age of disease onset \< 70 years
  • Clinical and biological diagnosis of AD based on
  • Progressive amnestic syndrome associated or not with other cognitive impairments
  • Biological criteria: CSF biomarkers suggestive of AD.
  • Brain MRI congruent with the diagnosis, left to the appreciation of the investigator
  • CDR (Clinical Dementia Rating Scale) = 0.5 or 1
  • If patients have an antidepressant or acetylcholinesterase inhibitors treatment, patients must be treated with stable doses of treatment for at least 1 month before inclusion.
  • Have a caregiver who provides a separate written informed consent to participate. If a caregiver/study informant cannot continue, one replacement is allowed.
  • Have adequate vision and hearing for neuropsychological testing in the opinion of the investigator.
  • Have given written informed consent approved by the ethical review board (ERB) governing the site.
  • The patient has to have a French social security number and be fluent and literate in French.

Exclusion Criteria23

  • Subject with a psychiatric evolutionary and/or badly checked.
  • Subject with a grave, severe or unstable pathology (left to the judgement of the investigator) the nature of which can interfere with the variables of evaluation.
  • Epileptic subjects
  • Subject under guardianship or curatorship
  • Subject presenting contraindications to the MRI
  • Known or supposed history (\< or = 5 years) of severe alcoholism or misuse of drugs
  • Vascular, inflammatory or expansive, visible lesion in the MRI, which can interfere on the criteria of diagnosis.
  • No health insurance
  • Women of childbearing potential: a woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.
  • History of auto-immune disease
  • History within the past 10 years of a primary or recurrent malignant disease
  • Diagnosis or history of other possible etiology of dementia, including but not limited to other neurodegenerative disorders (FTD, LBD, VaD, HD, PD, PSP-CBD).
  • Renal dysfunction at inclusion, clearance \<30 mL/min
  • Chronic hepatic diseases as indicated by liver function tests abnormalities
  • Abnormal thyroid function
  • Therapeutic trial within 1 year preceding the first study period, or participation in a trial with active or passive immunization against amyloid if patient was assigned to the active treatment arm.
  • Clinically significant evidence of Active viral infection (CMV, EBV, HCV, HBV, TPHA-VDRL, HIV)
  • Current or medical history of severe cardiopathy,
  • \- Severe dysfunction in a vital organ
  • Patients with White Blood Count (WBC) \< 4.000/mm3; platelets \< 100.000/mm3; hematocrit (HCT) \< 30%.
  • Patients with serum bilirubin and creatinine outside normal range.
  • Patients with organ allografts.
  • Patients who are likely to require corticosteroids

Interventions

DRUGProleukin

Sub-cutaneous injections of Interleukin-2 (PROLEUKIN ®) Induction phase: 5 consecutive days. A week break. Maintenance phase: once a week during 16 weeks

DRUGPlacebo

Sub-cutaneous injections of placebo (NaCl) Induction phase: 5 consecutive days. A week break. Maintenance phase: once a week during 16 weeks.

Locations(1)

GHU Saint Anne

Paris, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05468073

Related Trials

Novel Augmentation of DAOIB and Antioxidant for Early Dementia

NCT064675391 location

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

NCT06937229241 locations

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

NCT071782101 location

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

NCT041233141 location

A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)

NCT066577689 locations